Tone mix
Week by week 52 weeks
Share of CRISPR Therapeutics AG's 173 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Apr 13, 2026 · tone +992 Billion Reasons to Love CRISPR Therapeutics Right Now+79
- Week of Apr 20, 2026 · tone +100Positive Long-Term Outlook for Crispr Therapeutics as Gene Editing Portfolio Makes Progress+74
- Week of Jul 27, 2026 · tone +99Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?+67
- Week of Jul 13, 2026 · tone +993 Reasons to Buy CRISPR Therapeutics Stock+66
- Week of Nov 17, 2025 · tone +99Crispr Therapeutics gains amid takeover speculation (CRSP:NASDAQ)+61
- Week of Jun 22, 2026 · tone +99Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year+60
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about CRISPR Therapeutics AG in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 8 | -3 |
| Last 30 sessions | 23 | +9 |
| Last 90 sessions | 60 | +26 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
1 headline, average tone +73: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletCRISPR Therapeutics AG (NASDAQ:CRSP) Stock Has Average Price Target of $65.75 According to AnalystsPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Has Average Price Target of $65.75 According to Analysts | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletCRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and ExpositionNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletHead-To-Head Comparison: CRISPR Therapeutics (NASDAQ:CRSP) vs. Rallybio (NASDAQ:RLYB)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Head-To-Head Comparison: CRISPR Therapeutics (NASDAQ:CRSP) vs. Rallybio (NASDAQ:RLYB) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
3 headlines, average tone -33: 0 positive, 2 neutral and 1 negative. Showing all 3.
- www.tickerreport.com · 1 outletCRISPR Therapeutics (NASDAQ:CRSP) Announces Earnings Results, Misses Expectations By $0.11 EPSNegative
- www.themarketsdaily.com · 1 outletCRISPR Therapeutics (NASDAQ:CRSP) and Ernexa Therapeutics (NASDAQ:ERNA) Head to Head ReviewNeutral
- www.manilatimes.net · 1 outletCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| CRISPR Therapeutics (NASDAQ:CRSP) Announces Earnings Results, Misses Expectations By $0.11 EPS | www.tickerreport.com | 1 | Negative |
| CRISPR Therapeutics (NASDAQ:CRSP) and Ernexa Therapeutics (NASDAQ:ERNA) Head to Head Review | www.themarketsdaily.com | 1 | Neutral |
| CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.manilatimes.net · 1 outletCRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical OfficerNeutral
- www.themarketsdaily.com · 1 outletCRISPR Therapeutics AG $CRSP Position Increased by Profund Advisors LLCNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer | www.manilatimes.net | 1 | Neutral |
| CRISPR Therapeutics AG $CRSP Position Increased by Profund Advisors LLC | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about CRISPR Therapeutics AG, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.